{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:23Z","timestamp":1790890943862,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470206"],"award-info":[{"award-number":["82470206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104803","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T21:05:08Z","timestamp":1749157508000},"page":"104803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Challenges facing CAR T-cell immunotherapy in multiple myeloma"],"prefix":"10.1016","volume":"213","author":[{"given":"Wanyan","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-5437","authenticated-orcid":false,"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104803_bib1","first-page":"1","article-title":"Targeting refractory diffuse large b cell lymphoma by CAR-WEE1 T-cells: in vitro evaluation","author":"Ahmed","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR t cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104803_bib3","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.3390\/ijms21228620","article-title":"Engineering next-generation CAR-T cells for better toxicity management","volume":"21","author":"Andrea","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104803_bib4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMp1807382","article-title":"National coverage analysis of CAR-T therapies\u2014policy, evidence, and payment","volume":"379","author":"Bach","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR t cells with fully humanbinding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01374-5","article-title":"Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease","volume":"15","author":"Byun","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib7","first-page":"SP35","article-title":"With approval of CAR T-cell therapy comes the next challenge: payer coverage","volume":"24","author":"Caffrey","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.critrevonc.2025.104803_bib8","series-title":"Chimeric Antigen Receptor T Cells: Development and Production","first-page":"223","article-title":"Analysis of CAR-Mediated tonic signaling","author":"Calderon","year":"2020"},{"key":"10.1016\/j.critrevonc.2025.104803_bib9","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2024-204620","article-title":"Subgroup analyses of phase 2 study: evaluating the efficacy of fully human BCMA-Targeting CAR t cells (Zevorcabtagene Autoleucel) in patients with Relapsed\/Refractory multiple myeloma","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib10","first-page":"1039","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified t cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"43","key":"10.1016\/j.critrevonc.2025.104803_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-Cells: challenges and solutions","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib12","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR t cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2025.104803_bib13","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in t cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104803_bib14","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of t cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104803_bib15","article-title":"Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis","volume":"42","author":"Costa","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104803_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR t cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104803_bib18","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104803_bib19","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing On-Target Off-Tumor effects of CD38-Chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104803_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2217\/imt-2020-0181","article-title":"Chimeric antigen receptor t cells immunotherapy: challenges and opportunities in hematological malignancies","volume":"12","author":"El-Khazragy","year":"2020","journal-title":"Immunotherapy"},{"issue":"7709","key":"10.1016\/j.critrevonc.2025.104803_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted t cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104803_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2021-151935","article-title":"Integrated analysis of B-Cell maturation Antigen-Specific CAR t cells (CT053) in relapsed and refractory multiple myeloma subjects by High-Risk factors","volume":"138","author":"Fu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104803_bib24","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104803_bib25","article-title":"CAR-T cell treatment of high-risk multiple myeloma \u2013 will there be a cure?","author":"Gahrton","year":"2023","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104803_bib26","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR t cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR t cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104803_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-210350","article-title":"Real world outcomes with talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody: A single center experience for relapsed\/refractory multiple myeloma (RRMM)","volume":"114","author":"Gill","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104803_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor t cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104803_bib30","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-Cell lymphoma after CAR T-Cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104803_bib31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for Relapsed\/Refractory multiple myeloma: Real-World experience from the myeloma CAR t consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104803_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-Cell lymphoma after Cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104803_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/BTT.S291768","article-title":"Armored CAR T-Cells: the next chapter in T-Cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol. Targets Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-020-00166-2","article-title":"Interleukin-6-knockdown of chimeric antigen receptor-modified t cells significantly reduces IL-6 release from monocytes","volume":"9","author":"Kang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","article-title":"Improving drug delivery to solid tumors: priming the tumor microenvironment","volume":"201","author":"Khawar","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104803_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","author":"Kumar","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"7949","key":"10.1016\/j.critrevonc.2025.104803_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"9967","key":"10.1016\/j.critrevonc.2025.104803_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104803_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113919","article-title":"Nanobody-based CAR t cells targeting intracellular tumor antigens","volume":"156","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104803_bib42","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","author":"Lin","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12307-019-00232-2","article-title":"Tumor-infiltrating immunosuppressive cells in cancer-cell plasticity, tumor progression and therapy response","volume":"12","author":"Lorenzo-Sanz","year":"2019","journal-title":"Cancer Microenviron."},{"issue":"7786","key":"10.1016\/j.critrevonc.2025.104803_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR t cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104803_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor t cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104803_bib47","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR t cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib48","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an Anti\u2013B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for Relapsed\/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib49","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for Relapsed\/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: how to treat at diagnosis and relapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104803_bib51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104803_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor t cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104803_bib53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood-2023-190394","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"142","author":"Mi","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib54","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor\u2013T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib55","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-Label study of ciltacabtagene autoleucel, an Anti\u2013B-Cell maturation antigen chimeric antigen Receptor\u2013T-Cell therapy, in Chinese patients with Relapsed\/Refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib56","unstructured":"Miguel, S., 2022. Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104803_bib58","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2025.104803_bib61","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2023-177749","article-title":"Outcomes after CAR t cells in multiple myeloma patients with extramedullary and paramedullary disease","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"82","key":"10.1016\/j.critrevonc.2025.104803_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR t cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib64","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-Cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104803_bib65","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104803_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104803_bib67","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"issue":"620","key":"10.1016\/j.critrevonc.2025.104803_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR t cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104803_bib69","unstructured":"Qiang, W., Lu, J., Jia, Y., Liu, J., Liu, J., He, H., Wang, X., Fan, X., Jin, L., Ruan, Q. (n.d), B-Cell Maturation Antigen\/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma. JAMA oncology."},{"key":"10.1016\/j.critrevonc.2025.104803_bib70","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR t cell therapy bb21217 in patients with relapsed and refractory multiple myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104803_bib71","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","article-title":"The lymphoma-like polychemotherapy regimen \u201cDexa-BEAM\u201d in advanced and extramedullary multiple myeloma","volume":"93","author":"Rasche","year":"2014","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib73","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104803_bib74","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib76","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR t cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib78","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives t cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib80","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR t cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11899-018-0444-z","article-title":"Value-based care in hematopoietic cell transplantation and cellular therapy: challenges and opportunities","volume":"13","author":"Shah","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104803_bib82","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR t therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104803_bib83","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR t cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib84","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR t cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104803_bib85","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR t cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory b cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104803_bib87","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/bloodadvances.2019001287","article-title":"Chimeric antigen receptor\u2013T cells with cytokine neutralizing capacity","volume":"4","author":"Tan","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104803_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","article-title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents","author":"Touzeau","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib89","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","author":"Usmani","year":"2021","journal-title":"Wolters Kluwer Health"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib90","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-Cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104803_bib92","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR t therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104803_bib93","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR t cells","volume":"24","author":"Velasco C\u00e1rdenas","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib94","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1038\/s41467-020-18730-z","article-title":"Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence","volume":"11","author":"Walens","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104803_bib95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104803_bib96","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104803_bib97","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","article-title":"Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Xia","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104803_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib99","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR t cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104803_bib101","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"7926","key":"10.1016\/j.critrevonc.2025.104803_bib103","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104803_bib104","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104803_bib105","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jtct.2024.08.024","article-title":"Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-Cell therapy on the survival of patients with relapsed or refractory multiple myeloma","volume":"30","author":"Zhou","year":"2024","journal-title":"Transplant. Cell. Ther."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104803_bib106","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1182\/blood.V128.22.5724.5724","article-title":"CAR-T cell production using the Clinimacs\u00ae prodigy system","volume":"128","author":"Zhu","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104803_bib107","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor t cells using the CliniMACS prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:47:16Z","timestamp":1756154836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282500191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":107,"alternative-id":["S104084282500191X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104803","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges facing CAR T-cell immunotherapy in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104803"}}